Lorus announces presentation of corporate overview at the Rodman and Renshaw 8th Annual Healthcare Conference
06 Noviembre 2006 - 9:04AM
PR Newswire (US)
- Presentation available by web cast - TORONTO, Nov. 6
/PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. ("Lorus") (TSX:
LOR; AMEX: LRP), a biopharmaceutical company specializing in the
research and development of pharmaceutical products and
technologies for the management of cancer, announced today that Dr.
Aiping Young, President and CEO of Lorus, will provide a Company
update at the Rodman and Renshaw 8th Annual Healthcare Conference.
WHEN: November 8, 2006 WHERE: Kennedy II Room (4th floor) New York
Palace Hotel, New York, NY TIME: 10:15 a.m. Eastern Time Interested
parties may gain access to a live audio webcast of the presentation
by visiting the Investor Relations section of Lorus' website at
http://wsw.com/webcast/rrshq10/lrp, which will be available through
the same location through November 8, 2006. Lorus is one of over
300 invited companies to present at this conference held from
November 6 to 8, 2006. The conference provides informational
service and networking opportunities for healthcare companies and
investors. About Lorus Lorus is a publicly traded biopharmaceutical
company focused on the research and development of novel
therapeutics in cancer. Lorus' goal is to capitalize on its
research, preclinical, clinical and regulatory expertise by
developing new drug candidates that can be used, either alone, or
in combination, to successfully manage cancer. Through its own
discovery efforts and an acquisition and in-licensing program,
Lorus is building a portfolio of promising anticancer drugs.
Late-stage clinical development and marketing will be done in
cooperation with strategic pharmaceutical partners. Lorus has
completed one Phase II and one Phase III clinical trial. Lorus has
several product candidates in multiple Phase II clinical trials.
Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange
under the symbol LOR, and on the American Stock Exchange under the
symbol LRP. Forward Looking Statements This press release may
contain forward-looking statements within the meaning of Canadian
and U.S. securities laws. Such statements include, but are not
limited to, statements relating to: our expectations regarding
future financings, our plans to conduct clinical trials, the
successful and timely completion of clinical studies and the
regulatory approval process, our plans to obtain partners to assist
in the further development of our product candidates, the
establishment of corporate alliances, the Company's plans,
objectives, expectations and intentions and other statements
including words such as "continue", "believe", "plan", "expect",
"intend", "will", "should", "may", and other similar expressions.
Such statements reflect our current views with respect to future
events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by us are inherently subject to
significant business, economic, competitive, political and social
uncertainties and contingencies. Many factors could cause our
actual results, performance or achievements to be materially
different from any future results, performance, or achievements
that may be expressed or implied by such forward-looking
statements, including, among others: our ability to obtain the
capital required for research and operations; the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should the
assumptions set out in the section entitled "Risk Factors" in our
Annual Report underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein. Lorus Therapeutics Inc.'s
recent press releases are available through the Company's website
at http://www.lorusthera.com/. DATASOURCE: Lorus Therapeutics Inc.
CONTACT: Investor Relations: Lorus Therapeutics Inc., Dr. Saeid
Babaei, Phone: (416) 798-1200, x490, ; Media Relations: Mansfield
Communications, Susana Hsu, Phone: (416) 599-0024,
Copyright